Vertex is pleased to confirm that a funding application for Trikafta® (elexacaftor/tezacaftor/ivacaftor and ivacaftor)
has been made to PHARMAC.
This follows our recent submission earlier in June to Medsafe for the evaluation of Trikafta for the treatment of cystic
fibrosis (CF) in people ages 6 years and older. Medsafe granted priority review for the submission, which could see the
review time for the evaluation significantly reduced. PHARMAC previously agreed to review this funding application in
parallel to the Medsafe review.
Vertex is willing to work collaboratively and flexibly with PHARMAC and we look forward to dialogue and the next steps
in the process.
Vertex has made significant progress in New Zealand over the last few months and is committed to ensuring all eligible
patients have sustainable access to our triple combination treatment as soon as possible.
Note: Trikafta® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) is not a registered product in New Zealand and this
statement is for information purposes only.